References
- Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith Ai, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 15: 45–57.
- Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor LMO2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci USA 2000; 4: 320–324.
- Bach I. The LIM domain: regulation by association. Mech Dev 2000; 91: 5–17.
- Dong WF, Billia F, Atkins HL, Iscove NN, Minden MD. Expression of rhombotin 2 in normal and leukaemic haemopoietic cells. Br J Haematol 1996; 93: 280–286.
- Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is over-expressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991; 6: 1887–1893.
- Rabbitts TH. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev 1998; 12: 2651–2657.
- Natkunam Y, Farinha P, Hsi ED et al. LMO2 protein expressionpredicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008; 26: 447–454.
- Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronicmyelogenous leukaemia. Nat Rev Cancer 2005; 5: 172–183.
- Perrotti D, Calabretta B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002; 21: 8577–8583.
- Yamada Y, Warren Ai, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Nail Aced Sci USA 1998; 95: 3890–3895.
- Wadman IA, Osada H, Griitz GG et al. The LIM-only protein LMO2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TALI, E47, GATA-I and Ldbl/NLI proteins. EMBO J 1997; 16: 3145–3157.
- Vitelli L, Condorelli G, Lulli V et al. A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodu-lates c-kit expression in normal erythroblasts. Mol Cell Biol 2000; 20: 5330–5342.
- Izraeli S. Leukaemia-a developmental perspective. Br J Haematol 2004; 126: 3–10.
- Natkunam Y, Zhao S, Mason DY et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007; 109: 1636–1642.
- Kabarowski JH, Witte ON. Consequences of BCR-ABL expres-sion within the hematopoietic stem cell in chronic myeloid leukemia. Stem Cells 2000; 18: 399–408.
- Ramaraj P, Singh H, Niu N et al. Effect of mutational inactivationof tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res 2004; 64: 5322–5331.
- Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829–3840.
- Jiang X, Zhao Y, Smith C et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935.